Adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
IV 100-120mg/m2, given on Day 1 of cycle or divided into 2 doses and given on Day 1 and Day 8. It is repeated every 21–28 days for 6 cycles [in combination with other chemotherapy agents].
Consult specialist literature for further information.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is thought to inhibit DNA-dependent RNA synthesis by forming a complex with DNA through intercalation with guanine residues and impairing the template activity of DNA. It also has some immunosuppressive and hypocalcaemic activities.
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; to reduce the dose in case of impaired hepatic function; severe myelosup-pression with resulting infection or bleeding may occur; cardiac function should be monitored regularly
Myelosuppression [sometimes severe]; cardiac toxicity and congestive heart failure; secondary acute myelogenous leukemia [AML]; triad of back pain; flushing; and chest tightness; increased appetite; dysphagia; GI haemorrhage; gastritis; stomatitis; nausea and vomiting; gingival bleeding; hemorrhoids; melena; diarrhea; abdominal pain; anorexia; and constipation; dry mouth; taste perversion; thirst; hiccups; or tooth caries; neuropathy; amnesia; anxiety; ataxia; confusion; emotional lability; hallucination; hyperkinesias; hypertonia; tremor; somnolence; seizures; alopecia; pigmentation of finger nails and toenails; severe local tissue damage in extravasation; fever; myalgia; hypocalcaemia; hypersensitivity reactions.
It is an anthracycline glycoside antibiotic. It is a 4'-epimer of doxorubicin and a semi-synthetic derivative of daunorubicin.